Chiasma Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Chiasma stock.
View analyst ratings for Chiasma or view top-rated stocks.

Wall Street analysts have given Chiasma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Chiasma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Chiasma saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 2,490,000 shares, a decrease of 15.6% from the December 31st total of 2,950,000 shares. Based on an average trading volume of 1,030,000 shares, the short-interest ratio is presently 2.4 days.
View Chiasma's Short Interest.

Chiasma is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for Chiasma.

Chiasma will be holding an earnings conference call on Thursday, March 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Chiasma, Inc. (NASDAQ:CHMA) issued its earnings results on Thursday, November, 5th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.41) by $0.11. The biotechnology company had revenue of $0.14 million for the quarter.
View Chiasma's earnings history.

Chiasma's stock was trading at $3.92 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CHMA shares have increased by 0.8% and is now trading at $3.95.
View which stocks have been most impacted by COVID-19.

3 analysts have issued twelve-month price targets for Chiasma's shares. Their forecasts range from $8.00 to $15.00. On average, they expect Chiasma's share price to reach $11.00 in the next year. This suggests a possible upside of 178.5% from the stock's current price.
View analysts' price targets for Chiasma or view top-rated stocks among Wall Street analysts.

Some companies that are related to Chiasma include Five Prime Therapeutics (FPRX), Radius Health (RDUS), VBI Vaccines (VBIV), ESSA Pharma (EPIX), Prothena (PRTA), Kadmon (KDMN), Amphastar Pharmaceuticals (AMPH), ADVANZ PHARMA (CXRXF), Dyne Therapeutics (DYN), Esperion Therapeutics (ESPR), Collegium Pharmaceutical (COLL), AnaptysBio (ANAB), Rigel Pharmaceuticals (RIGL), Gossamer Bio (GOSS) and Merus (MRUS).
View all of CHMA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Companies (BHC), GW Pharmaceuticals (GWPH), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), Amarin (AMRN), Exelixis (EXEL) and Ovid Therapeutics (OVID).

(CHMA) raised $76 million in an initial public offering (IPO) on Thursday, July 16th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

Chiasma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.34%), Bruce & Co. Inc. (1.82%), The Manufacturers Life Insurance Company (1.38%), Ikarian Capital LLC (1.26%), Stonepine Capital Management LLC (1.25%) and Renaissance Technologies LLC (1.11%). Company insiders that own Chiasma stock include David M Stack, Raj Kannan, Roni Mamluk, Scott Minick and William Ludlam.
View institutional ownership trends for Chiasma.

CHMA stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Nuveen Asset Management LLC, Barclays PLC, and GSA Capital Partners LLP.
View insider buying and selling activity for Chiasma or view top insider-selling stocks.

CHMA stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Bruce & Co. Inc., BlackRock Inc., Healthcare of Ontario Pension Plan Trust Fund, Healthcare of Ontario Pension Plan Trust Fund, Stonepine Capital Management LLC, The Manufacturers Life Insurance Company , and State of Wisconsin Investment Board. Company insiders that have bought Chiasma stock in the last two years include David M Stack, Raj Kannan, Scott Minick, and William Ludlam.
View insider buying and selling activity for Chiasma or or view top insider-buying stocks.

Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CHMA stock can currently be purchased for approximately $3.95.

Chiasma has a market capitalization of $228.33 million. The biotechnology company earns $-36,320,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis.

Chiasma employs 85 workers across the globe.

The official website for Chiasma is www.chiasmapharma.com.

Chiasma is headquartered at 140 Kendrick Street Building C East, Needham MA, 02494.

Chiasma's mailing address is 140 Kendrick Street Building C East, Needham MA, 02494. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]